TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
Titel:
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
Auteur:
Plummer, Ruth Sodergren, Mikael H. Hodgson, Rose Ryan, Bríd M. Raulf, Nina Nicholls, Joanna P. Reebye, Vikash Voutila, Jon Sinigaglia, Laura Meyer, Tim Pinato, David J. Sarker, Debashis Basu, Bristi Blagden, Sarah Cook, Natalie Jeffrey Evans, Thomas R. Yachnin, Jeffrey Chee, Cheng E. Li, Daneng El-Khoueiry, Anthony Diab, Maria Huang, Kai-Wen Pai, Madhava Spalding, Duncan Talbot, Thomas Noel, Marcus S. Keenan, Bridget Mahalingam, Devalingam Song, Min-Sun Grosso, Mélanie Arnaud, Denis Auguste, Aurelie Zacharoulis, Dimitris Storkholm, Jan McNeish, Iain Habib, Robert Rossi, John J. Habib, Nagy A.